12:00 AM
Jun 21, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Jalyn dutasteride/tamsulosin regulatory update

FDA approved an NDA from GlaxoSmithKline for Jalyn dutasteride/tamsulosin to treat symptomatic benign prostatic hyperplasia (BPH) in men...

Read the full 68 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >